{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:30:53Z","timestamp":1792611053283,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of &amp;gt;2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral fracture. Significant reduction in incident vertebral fracture risk by 62% and 50%, respectively, was shown after 3 years. This is the first study to prospectively show antifracture efficacy for the intermittent administration of a bisphosphonate.<\/jats:p>\n               <jats:p>Introduction: Bisphosphonates are important therapeutics in postmenopausal osteoporosis. However, they are currently associated with stringent dosing instructions that may impair patient compliance and hence therapeutic efficacy. Less frequent, intermittent administration may help to overcome these deficiencies. This study assessed the efficacy and safety of oral ibandronate administered either daily or intermittently with a dose-free interval of &amp;gt;2 months.<\/jats:p>\n               <jats:p>Materials and Methods: This randomized, double-blind, placebo-controlled, parallel-group study enrolled 2946 postmenopausal women with a BMD T score \u2264 \u22122.0 at the lumbar spine in at least one vertebra (L1-L4) and one to four prevalent vertebral fractures (T4-L4). Patients received placebo or oral ibandronate administered either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months).<\/jats:p>\n               <jats:p>Results and Conclusions: After 3 years, the rate of new vertebral fractures was significantly reduced in patients receiving oral daily (4.7%) and intermittent ibandronate (4.9%), relative to placebo (9.6%). Thus, daily and intermittent oral ibandronate significantly reduced the risk of new morphometric vertebral fractures by 62% (p = 0.0001) and 50% (p = 0.0006), respectively, versus placebo. Both treatment groups also produced a statistically significant relative risk reduction in clinical vertebral fractures (49% and 48% for daily and intermittent ibandronate, respectively). Significant and progressive increases in lumbar spine (6.5%, 5.7%, and 1.3% for daily ibandronate, intermittent ibandronate, and placebo, respectively, at 3 years) and hip BMD, normalization of bone turnover, and significantly less height loss than in the placebo group were also observed for both ibandronate regimens. The overall population was at low risk for osteoporotic fractures. Consequently, the incidence of nonvertebral fractures was similar between the ibandronate and placebo groups after 3 years (9.1%, 8.9%, and 8.2% in the daily, intermittent, and placebo groups, respectively; difference between arms not significant). However, findings from a posthoc analysis showed that the daily regimen reduces the risk of nonvertebral fractures (69%; p = 0.012) in a higher-risk subgroup (femoral neck BMD T score &amp;lt; \u22123.0). In addition, oral ibandronate was well tolerated. Oral ibandronate, whether administered daily or intermittently with an extended between-dose interval of &amp;gt;2 months, is highly effective in reducing the incidence of osteoporotic fractures in postmenopausal women. This is the first time that significant fracture efficacy has been prospectively shown with an intermittently administered bisphosphonate in the overall study population of a randomized, controlled clinical trial. Thus, oral ibandronate holds promise as an effective and convenient alternative to current bisphosphonate therapies.<\/jats:p>","DOI":"10.1359\/jbmr.040325","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:44:52Z","timestamp":1146098692000},"page":"1241-1249","source":"Crossref","is-referenced-by-count":987,"title":["Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis"],"prefix":"10.1093","volume":"19","author":[{"suffix":"III","given":"Charles H","family":"Chesnut","sequence":"first","affiliation":[{"name":"Osteoporosis Research Group, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Skag","sequence":"additional","affiliation":[{"name":"Center for Clinical Trials, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Center for Clinical and Basic Research, Ballerup Byvej, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Recker","sequence":"additional","affiliation":[{"name":"Osteoporosis Research Center, Creighton University, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A","family":"Stakkestad","sequence":"additional","affiliation":[{"name":"CECOR AS, Haugesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Hoiseth","sequence":"additional","affiliation":[{"name":"Oslo Department, Sentrum R\u00f8ntgen Institut AS, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Felsenberg","sequence":"additional","affiliation":[{"name":"Universitatsklinikum Benjamin Franklin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Huss","sequence":"additional","affiliation":[{"name":"Leverkusen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gilbride","sequence":"additional","affiliation":[{"name":"F Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph C","family":"Schimmer","sequence":"additional","affiliation":[{"name":"F Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre D","family":"Delmas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Claude Bernard University, INSERM Research Unit 403, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"issue":"S1","key":"2024013019193681800_bib1","first-page":"S136","article-title":"Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites","volume":"6","author":"Melton","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024013019193681800_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF01623352","article-title":"Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES)","volume":"4","author":"Jones","year":"1994","journal-title":"Osteoporos Int"},{"issue":"Suppl 2A","key":"2024013019193681800_bib3","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(05)80037-3","article-title":"The economic and human costs of osteoporotic fracture","volume":"98","author":"Barrett-Connor","year":"1995","journal-title":"Am J Med"},{"issue":"Suppl 2","key":"2024013019193681800_bib4","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/PL00004164","article-title":"Bisphosphonates: Pharmacology, mechanisms of action and clinical uses","volume":"9","author":"Russell","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024013019193681800_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"N Engl J Med"},{"key":"2024013019193681800_bib6","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2024013019193681800_bib7","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2024013019193681800_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019193681800_bib9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med"},{"key":"2024013019193681800_bib10","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am J Manag Care"},{"key":"2024013019193681800_bib11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/B978-012470862-4\/50073-8","volume-title":"Osteoporosis","author":"Papapoulos","year":"2001","edition":"2nd ed."},{"issue":"Suppl 3","key":"2024013019193681800_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF01623002","article-title":"Clinical pharmacology of alendronate sodium","volume":"3","author":"Gertz","year":"1993","journal-title":"Osteoporos Int"},{"key":"2024013019193681800_bib13","first-page":"127","article-title":"The impact of adherence to osteoporosis therapy on fracture rates in actual practice","volume":"5","author":"Caro","year":"2002","journal-title":"Value Health"},{"issue":"Suppl 1","key":"2024013019193681800_bib14","first-page":"S32","article-title":"Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study","volume":"13","author":"Kendler","year":"2002","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"2024013019193681800_bib15","first-page":"S36","article-title":"Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis","volume":"13","author":"Palmisano","year":"2002","journal-title":"Osteoporos Int"},{"key":"2024013019193681800_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0149-2918(00)87974-6","article-title":"Weekly administration of alendronate: Rationale and plan for clinical assessment","volume":"22","author":"Bone","year":"2000","journal-title":"Clin Ther"},{"key":"2024013019193681800_bib17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"Muhlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024013019193681800_bib18","first-page":"2200","article-title":"Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J Rheumatol"},{"key":"2024013019193681800_bib19","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1359\/jbmr.1999.14.10.1768","article-title":"Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties","volume":"14","author":"Monier-Faugere","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024013019193681800_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S8756-3282(02)00923-7","article-title":"Intermittent IV administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Smith","year":"2003","journal-title":"Bone"},{"key":"2024013019193681800_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly IV injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thi\u00e9baud","year":"1997","journal-title":"Am J Med"},{"key":"2024013019193681800_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled, dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"2024013019193681800_bib23","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"Riis","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019193681800_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0149-2918(03)90005-1","article-title":"Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: A review of three phase II studies","volume":"25","author":"Schimmer","year":"2003","journal-title":"Clin Ther"},{"key":"2024013019193681800_bib25","first-page":"205","volume-title":"Vertebral Fracture in Osteoporosis","author":"Ross","year":"1995"},{"key":"2024013019193681800_bib26","first-page":"518","article-title":"Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures","volume":"10","author":"Kiel","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024013019193681800_bib27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/jbmr.5650110602","article-title":"Noninvasive assessment of bone mineral and structure: State of the art","volume":"11","author":"Genant","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019193681800_bib28","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/clinchem\/40.11.2022","article-title":"Immunoassay for quantifying type I collagen degradation products in urine evaluated","volume":"40","author":"Bonde","year":"1994","journal-title":"Clin Chem"},{"key":"2024013019193681800_bib29","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019193681800_bib30","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/clinchem\/41.10.1439","article-title":"Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies","volume":"41","author":"Rosenquist","year":"1995","journal-title":"Clin Chem"},{"key":"2024013019193681800_bib31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/clinchem\/39.4.648","article-title":"Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma","volume":"39","author":"Rosalki","year":"1993","journal-title":"Clin Chem"},{"key":"2024013019193681800_bib32","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019193681800_bib33","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2024013019193681800_bib34","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate phase III Osteoporosis Treatment study group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2024013019193681800_bib35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial study group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024013019193681800_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024013019193681800_bib37","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer; a double-blind placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"2024013019193681800_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0169-6009(91)90129-N","article-title":"Intermittent treatment with IV 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHButBP) in the therapy of postmenopausal osteoporosis","volume":"15","author":"Passeri","year":"1991","journal-title":"Bone Miner"},{"key":"2024013019193681800_bib39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01623227","article-title":"Two years effectiveness of IV pamidronate (APD) versus oral fluoride for osteoporosis occurring in the menopause","volume":"4","author":"Thi\u00e9baud","year":"1994","journal-title":"Osteoporos Int"},{"key":"2024013019193681800_bib40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jbmr.5650100505","article-title":"Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy","volume":"10","author":"Filipponi","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2024013019193681800_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis","volume":"322","author":"Storm","year":"1990","journal-title":"N Engl J Med"},{"key":"2024013019193681800_bib42","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by IV injection once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"2024013019193681800_bib43","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Clinical assessment of IV ibandronate injection once every 3 months in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.040325","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/8\/1241\/56473870\/5650190806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/19\/8\/1241\/56473870\/5650190806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:06:52Z","timestamp":1710342412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/19\/8\/1241-1249\/7592724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,1]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2004,8,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.040325","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,8,1]]},"published":{"date-parts":[[2004,8,1]]}}}